| Project/Area Number |
59480283
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Kinki University |
|---|
Principal Investigator |
IWASA Zenji (1985-1986) Kinki University, 医学部, 助教授 (20111031)
陣内 傳之助 (1984) 近畿大学, 医学部, 教授
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YASUTOMI Masayuki Kinki University, 医学部, 教授 (60028438)
中村 哲彦 近畿大学, 医学部, 助手 (00159071)
OKUNO Kiyotaka Kinki University, 医学部, 講師 (30169239)
NAKAMURA Tetsuhiko Kinki University
|
|---|
| Project Period (FY) |
1984 – 1986
|
| Project Status |
Completed (Fiscal Year 1986)
|
| Budget Amount *help |
¥6,000,000 (Direct Cost: ¥6,000,000)
Fiscal Year 1986: ¥1,700,000 (Direct Cost: ¥1,700,000)
Fiscal Year 1985: ¥1,700,000 (Direct Cost: ¥1,700,000)
Fiscal Year 1984: ¥2,600,000 (Direct Cost: ¥2,600,000)
|
|---|
| Keywords | Lymphokine-activated killer (LAK) cell / Metastasis / Tumor-bearing spleen / Lymphokine-activated killer(LAK)細胞 |
|---|
| Research Abstract |
Culture of human peripheral blood lymphocytes (PBL) in interleukin-2 (IL-2) qenerates cytotoxic effector cells which have a unique ability to lyse natural killer (NK)-resistant fresh human cancer cells. Rosenberg, et al. have labeled these effector cells as "Lymphokine-activated killer (LAK)" cells. The biologic role of LAK cells in unknown, though it is understood that they can lyse tumor cells both in vitro and in vivo assay (Winn assay).
The present study investigates the capability to generate LAK cells from the spleen of a gastric cancer patient and their resultant immunotherapeutic potential for inhibiting tumor cell growth. Spleen cells from a gastric cancer patient were cultured in IL-2 for 4 days and were then tested for lytic activity against several tumor targets in a 4-hr chromium-release assay. Significant lysis of tumor target cells was seen in effectors from cancer patient splenocytes as well as in those from non-cancerous splenocytes. Using IL-2, it is also possible to increase LAK cell count. Beginning with only <10^6> starting cells, 24 x <10^6> cells can be generated within 2 weeks.
Antitumor cytotoxicity was not diminished during the culture period. To examine in vivo efficacy, we injected the said effectors into the implanted tumor mass of nude mice. These effectors significantly inhibited tumor growth. The use of these IL-2 activated cells may prove to be a valuable tool in adoptive therapy of human neoplasms.
|
